This week in therapeutics




Licensing status

Publication and contact information

Infectious disease

Bacterial infection; candidiasis; malaria

Poly-N-acetylglucosamine (PNAG)

In vitro and mouse studies suggest an anti-PNAG antibody could help prevent infections from a range of pathogens. PNAG was expressed on the surface of Candida albicans, Neisseria meningitidis, Plasmodium species, Streptococcus pneumoniae, S. pyogenes and multiple other pathogens. In mouse models for C. albicans, N. meningitidis, S. pneumoniae,
S. pyogenes or P. burghei infection, pretreatment with the anti-PNAG antibody F598 decreased pathogen burden and markers of disease compared with control antibody or control serum. Ongoing work includes testing F598 against Escherichia coli K1, Group B Streptococcus and other pathogens that cause neonatal infections.
Alopexx Pharmaceuticals LLC and Sanofi have F598 (SAR279356) in Phase II testing to prevent bacterial infections.
Alopexx Vaccine LLC has a vaccine based on deacetylated PNAG in preclinical development to prevent bacterial infections in humans and animals (see PNAG: broadening infection protection, page 6).

SciBX 6(23); doi:10.1038/scibx.2013.579
Published online June 13, 2013

Patented by Brigham and Women's Hospital and Beth Israel Deaconess Medical Center; licensed to Alopexx Pharmaceuticals LLC and Sanofi

Cywes-Bentley, C. et al. Proc. Natl. Acad. Sci. USA; published online May 28, 2013;
Contact: Gerald B. Pier, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.